Quarterly Pricing Pulse — Q2 2026

AbbVie filed three material events in Q2 (May 12, April 29, and June 22) signaling aggressive restructuring of Botox and Juvéderm rebate programs under the Allē loyalty umbrella. This is the market bellwether: when the category leader tightens rebates or shifts volume incentives, every competitor follows. Expect rebate thresholds to rise, loyalty tiers to narrow, and per-unit payouts to compress. If you've relied on predictable rebate revenue to offset injectable costs, recalibrate your cost-per-unit assumptions now. AbbVie's moves typically cascade through the market within 60–90 days.

Evolus filed four material events (June 12, May 4, March 13, and earlier) emphasizing Jeuveau (Newtox) and the Evolus Rewards program, explicitly targeting medspas. This is classic price-war positioning: a smaller player with lower manufacturing costs undercutting the leader to gain share. Jeuveau's aggressive medspa-focused marketing and rebate structure are designed to pull volume away from Botox. If you're a Botox-heavy practice, Evolus is testing your price sensitivity. Evaluate Jeuveau's rebate terms and efficacy data; competitive pressure may force you to diversify toxin sourcing or renegotiate AbbVie terms.

Hims & Hers filed three material events (June 15, May 21, May 2) on compounded GLP-1 telehealth offerings. Eli Lilly filed three (May 20, May 7, April 30) on Zepbound/Mounjaro supply and compounding-rule changes. Together, these signal that telehealth platforms are capturing GLP-1 demand at lower price points than medspas can sustain. If you've added GLP-1 to your menu, you're now competing against national telehealth players with lower overhead. Expect continued pricing pressure and supply constraints. Medspas offering GLP-1 should focus on in-person support, customization, and bundling with aesthetic treatments to justify premium pricing.

Bausch Health (parent of Solta) filed three material events (May 19, April 29, March 2) hinting at potential spin-off or M&A activity. Solta owns Thermage, Fraxel, and Clear+Brilliant—key revenue drivers for many medspas. Corporate restructuring often precedes support and pricing changes. If Solta is spun off or acquired, expect shifts in rebate programs, training support, and parts availability. Practices relying on Solta equipment should diversify supplier relationships and lock in service contracts now, before any transition.

Multiple filler trials advanced this quarter (Restylane Lyft chin studies, Cellbooster Shape, Dr. Korman HA filler), but none signal imminent market disruption. Galderma and Merz continue iterative improvements (lidocaine formulations, new anatomical indications), but no new category-killer emerged. The filler market remains stable and mature. Pricing pressure here is competitive rather than innovation-driven. Maintain your current filler mix unless rebate terms shift materially; new entrants rarely displace established players in fillers as quickly as they do in toxins.

An FDA Class II recall of Payless Compounders' semaglutide products (lack of sterility assurance) is a stark reminder: compounded injectables carry regulatory and reputational risk. If you're sourcing compounded GLP-1, toxins, or fillers, verify supplier credentials, batch testing, and compliance. Regulatory tightening on compounding (signaled by Eli Lilly's material events) may narrow your sourcing options and raise costs. Stick with FDA-approved products where possible; if you compound, document chain-of-custody and quality assurance rigorously.